Nerviano Medical Sciences is focused on the discovery and early development of oncology drugs. Our business model is to partner our drugs at late preclinical or early clinical stage for full development and commercialization. Our mission is to pursue innovative therapeutic approaches in Oncology, discovering and developing molecules with novel mechanisms of action, for the advancement of personalized care of cancer patients. An experienced and lean management team leads a highly skilled staff of professionals with international experience and a broad range of expertise in R&D, combining the flexibility of a biotech with the quality standards of a big pharma.
We have fully integrated expertise to discover and develop new molecules from target identification and early discovery to IND / Phase I/II clinical trials with proven capability to bring innovative oncology drugs to the clinic. We cover all operational aspects of preclinical drug development and manufacturing through our affiliates.
We conduct our studies in collaboration with academic and clinical investigators worldwide and are open to research collaborations with pharmaceutical partners on novel targets and development of new drugs.
Our research is based on specialized drug discovery platforms with broad intellectual property, know-how and technologies, including the Kinase Platform and the Antibody-Drug Conjugates (ADC) Platform, that accelerate and facilitate our discovery programs.
Our current project portfolio consists of a balanced oncology pipeline that spans from discovery to early stage clinical projects suited for partnering or already partnered.